Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

Should Transplant Centers Prioritize Further Stem Cell Collection for Future CAR T-Cell Therapy Boosts? an Economic and Clinical Assessment

Ehsan Malek, Marco Davila, Hector Tirado, Shernan G. Holtan, Brian Betts, Han Yu

Blood (2024) 144 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2024-200893

Published: 2024

Journal Articles

A Novel Immunoproteasome Activator That Expands and Amplifies the Multiple Myeloma Immunopeptidome and Promotes Cytotoxic T-Cell Activity

James J. Driscoll, II, Ehsan Malek, Priyanka S. Rana, James J Ignatz-Hoover

Blood (2024) 144 (Supplement 1): 6832.

https://doi.org/10.1182/blood-2024-211485

Published: 2024

Journal Articles

Speeding up Myeloma Care: Robust Machine Learning Predictions of M-Spike Levels

Ehsan Malek, Juan Pablo Capdevila, Jennifer M. Ahlstrom, Jorge Arturo Hurtado Martinez, Gi-Ming Wang, Jay R. Hydren, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 7604.

https://doi.org/10.1182/blood-2024-200888

Published: 2024

Journal Articles

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Ehsan Malek, Kimberly Crasti, Grant Schofield, Shernan G. Holtan, Megan M Herr, Marco Davila, You-Wen Qian, Brian Betts, Mackenzie Lieberman, Jason Tong, Colin Chavel, Kelvin P. Lee, Scott Olejniczak

Blood (2024) 144 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2024-198255

Published: 2024

Journal Articles

Machine Learning in Myeloma: Do Racial Differences Influences Systemic Impact of Multiple Myeloma?

Hector Tirado, Jorge Arturo Hurtado Martinez, Jennifer M. Ahlstrom, Jay R. Hydren, Juan Pablo Capdevila, James J. Driscoll, II, Gi-Ming Wang, Ehsan Malek

Blood (2024) 144 (Supplement 1): 7840.

https://doi.org/10.1182/blood-2024-208026

Published: 2024

Journal Articles

The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial

Ehsan Malek, James J Ignatz-Hoover, Priyanka S. Rana, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 7042.

https://doi.org/10.1182/blood-2024-211233

Published: 2024

Journal Articles

PSMC2 Overexpression Promotes Synthetic Lethality Sensitizing Multiple Myeloma Cells to p97 Inhibition

James J Ignatz-Hoover, Pryianka Rana, John D'Cruz, E Ricky Chan, Ehsan Malek, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2024-211260

Published: 2024

Journal Articles

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

Blood (2024) 144 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2024-211352

Published: 2024

Journal Articles

A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort

Blood (2024) 144 (Supplement 1): 4828.

https://doi.org/10.1182/blood-2024-207459

Published: 2024

Journal Articles

Assessing a New Paradigm in Defining High Risk Precursor Disease State for Patients with Plasma Cell Dyscrasia: Fluctuating Monoclonal Protein

Rishi Chopra, Pingfu Fu, Jeries Kort, Ravikumar Kyasaram, Ehsan Malek

Blood (2023) 142 (Supplement 1): 6774.

https://doi.org/10.1182/blood-2023-172709

Published: 2023

Journal Articles

Assessing the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Risk-Stratifying Multiple Myeloma Patients for Autologous Stem Cell Transplantation

Jeries Kort, Sathya Sri Areti, Nikolas Naleid, Brenda W Cooper, Ehsan Malek

Blood (2023) 142 (Supplement 1): 6706.

https://doi.org/10.1182/blood-2023-190931

Published: 2023

Journal Articles

HDAC6 Inhibition Activates Proteasomes to Modulate the MHC Class I Immunopeptidome and Promote Antimyeloma Immunity

Priyanka S. Rana, James J. Ignatz-Hoover, Ehsan Malek, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 6586.

https://doi.org/10.1182/blood-2023-189262

Published: 2023

Journal Articles

An Immunoproteasome Activator That Increases MHC Class I Antigen Presentation to Enhance Anti-Tumor Immunity

James J. Driscoll, II, Priyanka S. Rana, Ehsan Malek, James J. Ignatz-Hoover

Blood (2023) 142 (Supplement 1): 3642.

https://doi.org/10.1182/blood-2023-189541

Published: 2023

Journal Articles

GEN3014 (HexaBody ®-CD38) in Anti-CD38 Mab-Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial

Sebastian Grosicki, Torben Plesner, Wojciech Jurczak, Jakub Radocha, Ehsan Malek, Ida Hiemstra, Lauren K. Brady, Jenny Chen, Nian Gong, Charlotte Hindsberger, Andrew Spencer

Blood (2023) 142 (Supplement 1): 4757.

https://doi.org/10.1182/blood-2023-179504

Published: 2023

Journal Articles

PSMC2 Overexpression Enhances Proteasome Activity, Mitigates ER Stress, and Correleates with Reduced Overall Survival in Multiple Myeloma

James J. Ignatz-Hoover, E Ricky Chan, Jack D'Cruz, Pryianka Rana, Ehsan Malek, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 6617.

https://doi.org/10.1182/blood-2023-190462

Published: 2023

Journal Articles

Leveraging Artificial Intelligence to Uncover Hidden Biases in Survival Disparities of Patients with Multiple Myeloma

Ehsan Malek, Rishi Chopra, James J. Driscoll, II, Pingfu Fu

Blood (2023) 142 (Supplement 1): 7409.

https://doi.org/10.1182/blood-2023-172712

Published: 2023

Journal Articles

Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma

Ehsan Malek, Priyanka S. Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J. Ignatz-Hoover, Leland Metheny, Seong-Jin Kim, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 4749.

https://doi.org/10.1182/blood-2023-172711

Published: 2023

Journal Articles

Immune Profiling and Responses of Smoldering Multiple Myeloma Patients Treated in a Phase Ib Study of Pvx-410 Vaccine Targeting XBP1/CD138/CS1 Antigens, and Citarinostat, a Histone Deacetylase Inhibitor (HDACi) with and without Lenalidomide

Diana Cirstea, Rajib Shome, Joseph James Connolly, Emilie Duvallet, Amanda N. R. Joyce, Victor Moyo, Kathleen Lively, Gina Basinsky, Andrew J. Yee, Cristiana Costa Chase, Ehsan Malek, Ruben Niesvizky, Paul G. Richardson, Noopur S. Raje

Blood (2023) 142 (Supplement 1): 2017.

https://doi.org/10.1182/blood-2023-189332

Published: 2023

Journal Articles

Toward AI-Assisted Clinical Assessment for Patients with Multiple Myeloma: Feature Selection for Large Language Models

Ehsan Malek, Gi-Ming Wang, Anant Madabhushi, Jennifer Cullen, Curtis Tatsuoka, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 2328.

https://doi.org/10.1182/blood-2023-172710

Published: 2023

Journal Articles

Utilizing a Machine Learning Approach to Define Racial Difference in Multi-Systemic Impact of Monoclonal Protein in Patient with Multiple Myeloma

Ehsan Malek, Gi-Ming Wang, Jennifer Cullen, Curtis Tatsuoka, Anant Madabhushi, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 7343.

https://doi.org/10.1182/blood-2023-172742

Published: 2023

NARROW

Should Transplant Centers Prioritize Further Stem Cell Collection for Future CAR T-Cell Therapy Boosts? an Economic and Clinical Assessment

A Novel Immunoproteasome Activator That Expands and Amplifies the Multiple Myeloma Immunopeptidome and Promotes Cytotoxic T-Cell Activity

Speeding up Myeloma Care: Robust Machine Learning Predictions of M-Spike Levels

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Machine Learning in Myeloma: Do Racial Differences Influences Systemic Impact of Multiple Myeloma?

The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial

PSMC2 Overexpression Promotes Synthetic Lethality Sensitizing Multiple Myeloma Cells to p97 Inhibition

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort

Assessing a New Paradigm in Defining High Risk Precursor Disease State for Patients with Plasma Cell Dyscrasia: Fluctuating Monoclonal Protein

Assessing the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Risk-Stratifying Multiple Myeloma Patients for Autologous Stem Cell Transplantation

HDAC6 Inhibition Activates Proteasomes to Modulate the MHC Class I Immunopeptidome and Promote Antimyeloma Immunity

An Immunoproteasome Activator That Increases MHC Class I Antigen Presentation to Enhance Anti-Tumor Immunity

GEN3014 (HexaBody ®-CD38) in Anti-CD38 Mab-Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial

PSMC2 Overexpression Enhances Proteasome Activity, Mitigates ER Stress, and Correleates with Reduced Overall Survival in Multiple Myeloma

Leveraging Artificial Intelligence to Uncover Hidden Biases in Survival Disparities of Patients with Multiple Myeloma

Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma

Immune Profiling and Responses of Smoldering Multiple Myeloma Patients Treated in a Phase Ib Study of Pvx-410 Vaccine Targeting XBP1/CD138/CS1 Antigens, and Citarinostat, a Histone Deacetylase Inhibitor (HDACi) with and without Lenalidomide

Toward AI-Assisted Clinical Assessment for Patients with Multiple Myeloma: Feature Selection for Large Language Models

Utilizing a Machine Learning Approach to Define Racial Difference in Multi-Systemic Impact of Monoclonal Protein in Patient with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only